Medical news and careers, clearly connected
CareZelo
English
Menu

Medical technology & trends

RecallTech & trendsCanada

Beckman Coulter clinical analyzers may reset calculated test rules after software updates

Beckman Coulter reports that DxC 500i and DxC 500 AU clinical chemistry analyzers may revert custom calculated rules to default settings following software or parameter package upgrades. Operators who have modified these 25 predefined rules must verify settings after any system updates.

If you use these analyzers, check your calculated test rules after any software or parameter package updates to ensure they remain correctly configured.

Ask about this brief

Answers are written by AI from this brief and can be wrong. Check the original source before you act.

2 free questions a day without an account. Members ask as often as they like, free.

Not medical, legal or immigration advice. Questions are kept anonymously to improve our briefs.

Read the original

Official source: Beckman Coulter clinical analyzers may reset calculated test rules after software updates (opens in a new tab) — Health Canada recalls and alerts

Report a problem

RecallTech & trendsCanada

Abbott issues security update for FreeStyle Libre 3 mobile app

Abbott has released a mandatory security update for the FreeStyle Libre 3 app on Android and iOS. A previous patch to address a vulnerability caused a defect that may lead to prolonged communication loss between the app and the sensor. Users must update to version 3.6.10 immediately to resolve this issue.

If you assist patients using this system, ensure they update their app to version 3.6.10 to prevent sensor connection failures.

Official source: Health Canada recalls and alerts (opens in a new tab)

RecallTech & trendsCanada

Medtronic updates instructions for Abre venous stent system deployment

Medtronic has issued a recall to update the instructions for use for the Abre venous self-expanding stent system. The update provides a validated manual deployment method to address rare instances of partial stent deployment. No product returns or disposals are required.

If you use this device, review the new manual deployment instructions provided by the manufacturer to manage potential partial stent deployment.

Official source: Health Canada recalls and alerts (opens in a new tab)

ResearchTech & trendsCanada

Personalized mRNA vaccine reduces melanoma recurrence risk in clinical trial

Moderna and Merck's personalized mRNA vaccine intismeran cut the risk of melanoma returning by 42 per cent two years after surgery, in a study of more than 1,100 people with high-risk melanoma. Two years on, 82 per cent of vaccinated patients were recurrence-free, versus 70 per cent on Keytruda alone. The companies are discussing approval with regulators; full results were due at a European oncology meeting in Madrid.

A personalized mRNA vaccine, matched to each patient's tumour, is moving toward approval after a large trial showed a clear gain in living without recurrence.

News source: CBC News (opens in a new tab)